MENU
+Compare
ESPR
Stock ticker: NASDAQ
AS OF
Dec 23, 10:58 AM (EDT)
Price
$2.26
Change
+$0.07 (+3.20%)
Capitalization
495.94M

ESPR Esperion Therapeutics Forecast, Technical & Fundamental Analysis

a developer of biopharmaceutical products

ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for ESPR with price predictions
Dec 20, 2024

ESPR's RSI Oscillator leaves overbought zone

The 10-day RSI Oscillator for ESPR moved out of overbought territory on December 10, 2024. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 13, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ESPR as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ESPR turned negative on December 12, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

ESPR moved below its 50-day moving average on December 18, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESPR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ESPR broke above its upper Bollinger Band on December 02, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 50-day moving average for ESPR moved above the 200-day moving average on December 05, 2024. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ESPR advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 152 cases where ESPR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (58.252). P/E Ratio (0.000) is within average values for comparable stocks, (90.460). ESPR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.947). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (2.473) is also within normal values, averaging (19.472).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ESPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ESPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

View a ticker or compare two or three
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ESPR is expected to report earnings to fall 7.73% to -13 cents per share on February 27

Esperion Therapeutics ESPR Stock Earnings Reports
Q4'24
Est.
$-0.14
Q3'24
Beat
by $0.03
Q2'24
Missed
by $0.17
Q1'24
Beat
by $0.29
Q4'23
Missed
by $0.03
The last earnings report on November 07 showed earnings per share of -15 cents, beating the estimate of -17 cents. With 540.21K shares outstanding, the current market capitalization sits at 495.94M.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceutical products

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
3891 Ranchero Drive
Phone
+1 734 887-3903
Employees
240
Web
https://www.esperion.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FUNYX35.810.33
+0.93%
Pioneer Fundamental Growth Y
DTSVX25.570.16
+0.63%
Wilshire Small Company Value Invmt
MNOSX32.300.20
+0.62%
Manning & Napier Overseas Series S
MEMLX13.830.03
+0.22%
Morgan Stanley Inst EMkts Ldrs C
GSUKX17.47N/A
N/A
Goldman Sachs International Eq Inc R6

ESPR and Stocks

Correlation & Price change

A.I.dvisor tells us that ESPR and PTPI have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and PTPI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
+0.69%
PTPI - ESPR
29%
Poorly correlated
-5.67%
ZOM - ESPR
26%
Poorly correlated
+4.42%
EVO - ESPR
26%
Poorly correlated
+1.59%
SCYX - ESPR
26%
Poorly correlated
-1.00%
CTLT - ESPR
26%
Poorly correlated
N/A
More